874302-76-8

Usage

Uses

Used in Organic Synthesis:
4-nitrophenyl 2-(2-(pyridin-2-yl)disulfanyl)ethyl carbonate is used as a reagent in organic synthesis for the formation of disulfide bonds in peptides and proteins. Its ability to facilitate the creation of these bonds is crucial for the development of certain pharmaceuticals and organic materials.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 4-nitrophenyl 2-(2-(pyridin-2-yl)disulfanyl)ethyl carbonate is utilized in the development of new drugs. Its potential application in this field is attributed to its capacity to form disulfide bonds, which are important for the stability and function of various bioactive molecules.
Used in Redox Reaction Studies:
4-nitrophenyl 2-(2-(pyridin-2-yl)disulfanyl)ethyl carbonate is also used in the study of redox reactions. Its disulfide bond makes it a suitable candidate for investigating the mechanisms and kinetics of redox processes, which are fundamental to numerous chemical and biological systems.
Used in the Preparation of Functionalized Polymers:
Furthermore, 4-nitrophenyl 2-(2-(pyridin-2-yl)disulfanyl)ethyl carbonate has applications in the preparation of functionalized polymers. The incorporation of 4-nitrophenyl 2-(2-(pyridin-2-yl)disulfanyl)ethyl carbonate into polymer structures can impart specific properties, such as enhanced stability or reactivity, which are desirable for various applications in materials science.

Upstream product

• 111625-28-6 2-(2-(Pyridin-2-yl)disulfanyl)ethanol 
• 7693-46-1 4-Nitrophenyl chloroformate 
• 5070-13-3 bis-(p-nitrophenyl) carbonate 
• 2637-34-5 2-Sulfanylpyridine 
• 2127-03-9 2,2'-dipyridyldisulphide 

Downstream Products

• 1369516-09-5 2'-(2-(2-(pyridin-2-yl)disulfanyl)ethylcarbonate)docetaxel 
• 1032313-88-4 C₅₅H₅₈N₂O₁₆S₂ 

Relevant academic research and scientific papers

Multifunctionalization of magnetic nanoparticles for controlled drug release: A general approach

In this study, a general approach for the multifunctionalization of magnetic nanoparticles (MNPs) with drugs (Doxorubicin and Gemcitabine) and targeting moieties (Nucant pseudopeptide) for controlled and selective release is described. The functionalizati

Conjugation Chemistry-Dependent T-Cell Activation with Spherical Nucleic Acids

Spherical nucleic acids (SNAs) can be potent sequence-specific stimulators of antigen presenting cells (APCs). When loaded with peptide antigens, they can be used to activate the immune system to train T-cells to specifically kill cancer cells. Herein, th

GLP1R AGONIST NMDAR ANTAGONIST CONJUGATES

The present invention relates to a conjugated molecule comprising a peptide displaying at least 0.1% activity of native glucagon-like peptide 1 (GLP-1) at the GLP-1 receptor, and an N-methyl-D-aspartate receptor (NMDAR) antagonist, the peptide being coval

CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE

The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.

ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME

The present invention provides drug modifications for improving biodistribution and/or specificity of an anticancer drug. In certain embodiments, the compound of the invention comprises a drug, a linker and a core acid. The core acid can be varied to tune

Amplified Self-Immolative Release of Small Molecules by Spatial Isolation of Reactive Groups on DNA-Minimal Architectures

Triggering the release of small molecules in response to unique biomarkers is important for applications in drug delivery and biodetection. Due to low quantities of biomarker, amplifying release is necessary to gain appreciable responses. Nucleic acids have been used for both their biomarker-recognition properties and as stimuli, notably in amplified small-molecule release by nucleic-acid-templated catalysis (NATC). The multiple components and reversibility of NATC, however, make it difficult to apply in vivo. Herein, we report the use of the hybridization chain reaction (HCR) for the amplified, conditional release of small molecules from standalone nanodevices. We couple HCR with a DNA-templated reaction resulting in the amplified, immolative release of small molecules. We integrate the HCR components into single nanodevices as DNA tracks and spherical nucleic acids, spatially isolating reactive groups until triggering. This could be applied to biosensing, imaging, and drug delivery.

POLYMERIC CONJUGATES AND USES THEREOF

The present invention relates to novel chemical entities comprising a polymeric carrier incorporating covalently linked drug(s) as well as their pharmaceutical compositions containing the said polymer-drug conjugates as pharmaceutical agents and their use

Reduction response type Her2-targeting polypeptide drug conjugate as well as preparation method and application thereof

The invention relates to a reduction response type Her2-targeting polypeptide drug conjugate as well as a preparation method and application thereof. The polypeptide drug conjugate has the molecular structural formula shown in a formula I, wherein Aaa1 is

CONJUGATION OF PEPTIDES TO SPHERICAL NUCLEIC ACIDS (SNAS) USING TRACELESS LINKERS

The present disclosure provides compositions and methods directed to combining spherical nucleic acid (SNA) components that are required for T-cell activation and proliferation.

BICYCLIC PEPTIDE LIGAND PRR-A CONJUGATES AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.